Financing co-led by Taiho Ventures and Arkin Bio Capital with significant participation from other new and existing investorsInvestment enables continued clinical development of T-Bolt™ therapies, ...

A new AI tool that models how variations in peptides change T cell receptor binding could help design immunotherapies with fewer off-target effects. Protein complexes that adorn the surface of T cells ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T persistence and function. Additionally, there is a growing trend towards ...

Benezech et al. (Nov. 30 issue) 1 describe cases of six children in the pre–Covid-19 era who presented with an acute inflammatory syndrome and increased T-cell receptor (TCR) expression of Vβ21.3. The ...

This article and associated images are based on a poster originally authored by Alex Chenchik, Lester Kobzik, Tianbing Liu, Dongfang Hu, Kitt Paraiso, Khadija Ghias, and Paul Diehl and presented at ...

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 8, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, provides a progress ...

COLD SPRING HARBOR, N.Y., July 28, 2025 /PRNewswire/ -- Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a ...